Phase I study of rubitecan and gemcitabine in patients with advanced malignancies

Annals of Oncology

Volumn 13, Issue 11, 2002, Pages 1819-1825

  Fracasso, P M ^a   Rader, J S ^a   Govindan, R ^a   Herzog, T J ^a   Arquette, M A ^a   Denes, A ^a   Mutch, D G ^a   Picus, J ^a   Tan, B R ^a   Fears, C L ^a   Goodner, S A ^a   Sun, S L ^a  

^a Washington University in St Louis School of Medicine   (United States)

Author keywords

9 Nitrocamptothecin; Gemcitabine; Gemzar ; Orethecin ; Phase I; Rubitecan

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CYTARABINE DERIVATIVE; GEMCITABINE; IRINOTECAN; RUBITECAN; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG CANCER; MALAISE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CAMPTOTHECIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036861917     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf342     Document Type: Article

References (38)

1. Jaxel C, Kohn KW, Wani MC et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem 1994; 269: 2433-2439.
2. Gottleib JA, Guarino AM, Call JB et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium. Cancer Chemother Rep 1970; 54: 461-470.
3. Pantazis P, Mendoza JT, Early JA. 9-Nitro-camptothecin delays the growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. Eur J Haematol 1993; 50: 81-89.
4. Pantazis P, Hinz HR, Mendoza JT et al. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 1992; 52: 3980-3987.
5. Pantazis P, Early JA, Kozielski AJ et al. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitro-camptothecin: differential response of nontumorigenic and tumorigenic human breast cancer cells in vitro. Cancer Res 1993; 53: 1577-1582.
6. Pantazis P, Kozielski AJ, Mendoza JT et al. Camptothecin derivatives induce regression of human ovarian carcinoma grown in nude mice and distinguish between nontumorigenic and tumorigenic cells in vitro. Int J Cancer 1993; 53: 863-871.
7. Pantazis P, Kozielski A, Rodriguez R. Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 1994; 4: 5-10.
8. Liehr JG, Ahmed AE. Pharmacokinetics of camptothecins administered orally. Ann N Y Acad Sci 1996; 803: 157-163.
9. RFS 2000 Clinical Brochure. SuperGen, Inc., Dublin, CA. October 28, 1998.
10. Verschraegen CF, Natelson EA, Giovanella BC et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998; 9: 36-44.
11. Stehlin JS, Giovanella BC, Natelson EA et al. A study of 9-nitro-camptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14: 821-831.
12. Verschraegen CF, Gupta E, Loyer E et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs 1999; 10: 375-383.
13. van Moorsel CJA, Peters GJ, Pinedo HM. Gemcitabine: future prospects of single-agent and combination studies. Oncologist 1997; 2: 127-134.
14. Rosenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996; 7: 347-353.
15. Burris HA 3rd, Moore MJ, Andersen J et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
16. Anderson H, Lund B, Bach F et al. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer. J Clin Oncol 1994; 13: 1821-1826.
17. Perng RP, Chen YM, Liu JM et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J Clin Oncol 1997; 15: 2097-2102.
18. Stadler W, Kuzel T, Raghavan D et al. A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 1995; 14: 638.
19. Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-1533.
20. Carmichael J, Possinger K, Philip P et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-2736.
21. Bahadori HR, Rocha Lima CS, Green MR et al. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999; 19: 5423-5428.
22. Grunewald R, Abbruzzese JL, Tarassoff P et al. Saturation of 2′,2′-difluordeoxycytidine 5′triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27: 258-262.
23. Grunewald R, Kantarjian H, Keating MJ et al. Pharmacologically directed design of the dose rate and schedule of 2′, 2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 1990; 50: 6823-6826.
24. Grunewald R, Kantarjian H, Du M et al. Gemcitabine in leukemia: a phase I clinical plasma, and cellular pharmacology study. J Clin Oncol 1992; 10: 406-413.
25. Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 1997; 15: 331-341.
26. Gandhi V, Plunkett W, Du M et al. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 2002; 20: 665-673.
27. Touroutoglou N, Gravel D, Raber MN et al. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 1998; 9: 1003-1008.
28. Akrivakis K, Schmid P, Flath B et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 1999; 10: 525-531.
29. Schmid P, Akrivakis K, Flath B et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999; 10: 625-631.
30. Cascinu S, Frontini L, Labianca R et al. A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2000; 11: 1309-1311.
31. Sezer O, Eucker J, Jakob C et al. Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs 2001; 19: 101-104.
32. Kornek GV, Pötter R, Selzer E et al. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys 2001; 49: 665-671.
33. Patel SR, Gandhi V, Jenkins J et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 19: 3483-3489.
34. Rocha Lima CMS, Leong S-S, Sherman CA et al. Phase I study of CPT-11 and gemcitabine in patients with solid tumors. Cancer Ther 1999; 2: 58-66.
35. O'Reilly EM. Combination gemcitabine and irinotecan in advanced solid tumor malignancies. Preliminary results of a phase I trial. Cancer Conf Highlights 2000; 4: 11-13.
36. Rocha Lima CMS, Eckardt JR, Leong S-S et al. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin Oncol 1999; 26 (Suppl 16): 43-50.
37. Rocha Lima CMS, Sherman CA, Brescia FJ et al. Irinotecan/ gemcitabine combination chemotherapy in pancreatic cancer. Oncology 2001; 15 (Suppl 5): 46-51.
38. Rocha Lima CMS, Savarese D, Bruckner H et al. Irinotecan plus gemcitabine induces both radiographic and CA19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-1191.